????
Conditions
Interventions
Test group:Controlled group
Sponsors
Cancer hosptial Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically confirmed colorectal cancer patients; 2. It is planned to use the targeted drug regorafenib for the first time, and the initial dose is 120mg/d; 3. PS score = 3; 4. Aged = 18; 5, no intellectual and mental disorders, normal language expression ability, ability to judge their own symptoms 6. Understand and agree to accept the treatment, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with skin reactions affected by simultaneous use of other targeted drugs (sorafenib, sunitinib, fruquintinib, etc.), chemotherapy drugs (capecitabine, doxorubicin, etc.) or hand-foot radiotherapy; 2. Patients with skin diseases such as eczema, psoriasis and tinea pedis at observed skin sites (namely hands and feet); Patients with skin allergic diseases; 3. Patients in the study who cannot cooperate with the continuation of this treatment; 4. Sudden changes in the patient's condition affected and interfered with the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 3 hand and foot skin reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;Rate of reduction, discontinuation, or discontinuation of regorafenib;Incidence of grade 1-2 hand and foot skin reaction;Disease control rate; | — |
Countries
China
Contacts
Public ContactAIPING TIAN
Cancer hosptial Chinese Academy of Medical Sciences
Outcome results
None listed